Non-tuberculous mycobacteria (NTM) in Zambia: prevalence, clinical, radiological and microbiological characteristics

Pascalina Chanda-Kapata1,2*, Nathan Kapata2,3, Eveline Klinkenberg4,5, Lutinala Mulenga6, Mathias Tembo7, Patrick Katemangwe8, Veronica Sunkutu9, Peter Mwaba1 and Martin P. Grobusch2

Abstract
Background: Non-tuberculous mycobacteria (NTM) infection is an emerging health problem. We present here the Zambia-specific national level data of prevalence, symptomatic, radiological and microbiological characteristics of NTM, using results from a national Tuberculosis (TB) prevalence survey.

Methods: This was a cross-sectional study of the prevalence of NTM among adults aged 15 years and above, who were participants in a national TB prevalence survey. Participants who had either an abnormal chest x-ray or were symptomatic were considered presumptive TB cases and submitted sputum for smear and culture analysis. HIV testing was performed on an opt-out basis. Symptomatic NTM prevalence was estimated from individual level analysis.

Results: Of the 6,123 individuals with presumptive TB, 923 (15.1 %) were found to have NTM, 13 (0.2 %) were MTB/NTM co-infected and 338 (5.5 %) were contaminated (indeterminate). The prevalence of symptomatic NTM was found to be 1,477/100,000 [95 % CI 1010–1943]. Smear positivity, history of cough or chest pain and HIV positivity were risk factors for NTM.

Conclusion: This first study to estimate the national prevalence of NTM in Zambia indicates that the burden is high. The NTM occurrence in Zambia constitutes both a public health and ethical issue requiring action from health managers.

Keywords: Epidemiology, Survey, Non-tuberculous mycobacteria, Emerging, Public health, Diagnosis

Background
Non-tuberculosis Mycobacteria (NTM) refer to all Mycobacterium species other than the pathogens of the M. tuberculosis complex (MTBC), M. leprae and M. ulcerans, and rarely cause disease in humans. However, they may cause disease in individuals with pre-existing lung disease or immunodeficiency while some species may cause disease in elderly women without underlying pulmonary disease or immunodeficiency [1, 2]. NTM are commonly found in the environment and can be isolated from sources such as soil, milk, dust, animals and birds [1]. Over 140 species of NTM have been reported in literature with the majority of these species rarely being isolated in clinical samples [3]. The most common group of NTM is the Mycobacterium avium complex (MAC) comprising the clinically important members M. intracellulare, M. avium and M. chimaera. Other potentially pathogenic NTM species include M. chelonae, M. kansasii, M. xenopi, M. marinum, M. abscessus and M. fortuitum [4–6].

Among the diseases caused by NTM, pulmonary disease is the most frequent, followed by lymphadenitis in children, skin disease caused by Mycobacterium marinum (especially common in fish tank owners) and other extra-pulmonary or disseminated infections [3, 5, 7]. NTM can exhibit clinical and radiographic features that are similar to those by MTBC [8, 9] especially in persons with progressed cellular immune dysfunction. Although this is not the case in all studies, in Brazil, Dos Santos
and colleagues [10] compared radiological features between MTBC and NTM and found some differences in patients with AIDS. Species differentiation is needed to tell NTMs safely apart from MTBC in individuals suggestive of having TB [11]. However, distinguishing between MTBC and NTM diseases may be a challenge, especially in low resource settings where microscopy is the mainstay for MTBC diagnosis. Although microscopy for acid-fast bacilli (AFB) allows for rapid diagnosis of mycobacteria, it does not, however, differentiate \textit{M. tuberculosis} from NTM. A recent study in Nigeria [12] showed that failure to characterize AFB positive NTM lung infections has led to misclassification and incorrect treatment as pulmonary tuberculosis since all diagnosed sputum smear positive patients are placed on TB treatment. In order to differentiate the two, traditional culture methods may be required but these may take up to 6 weeks [13].

There is limited literature available on the extent of the burden of pulmonary disease due to NTM in sub-Saharan Africa. Studies conducted in the later part of the 1950s and early 1960s [14] identifying mycobacterial groups using traditional tools like characteristics such as growth rate and morphology reported the isolation of NTM from both tuberculosis patients and the general public in some African countries, Zambia included. The study as a whole found that the frequency of NTM strains differed; 19.8 % NTM cases were identified among 657 cultures isolated from specimens of a general population survey, whereas only 1.1 % NTM cases were identified from 7,580 cultures from tuberculosis patients. Studies conducted in Nigeria and Tanzania suggest NTM infections could be associated with HIV co-infection [15–17]. A prospective cohort study among HIV positive patients in Cote d’Ivoire reported a 10 times higher incidence of NTM infection among patients with baseline CD4 cell counts below 100 cells/mm$^3$ [18].

In Zambia, clinically relevant infection due to NTM was shown to occur in both HIV-positive and HIV-negative patients in a rural hospital [19]. In another study, Buijtels and colleagues [20] evaluated the clinical relevance of NTM isolated from chronically ill patients and healthy controls in Zambia and found that the proportion of NTM-positive sputum samples was significantly higher in the patient group (11 %) than in controls (6 %). The most frequently isolated NTM was \textit{M. avium} complex. Unlike HIV, sex and age; being underweight and consumption of tap water were identified as risk factors for NTM infection.

While it is acknowledged that the prevalence and the species of NTM isolated is increasing [5, 7, 8], the clinical relevance and characteristics of the NTMs in different settings remain to be established.

We present here the Zambia-specific data on national level prevalence, symptomatic, radiological and microbiological characteristics of NTMs, using results from a national Tuberculosis prevalence survey. To our knowledge, this is the first large data set to explore the prevalence of NTM from a national representative sample covering all provinces and to discuss radiological characteristics of NTM in Zambia.

**Methods**

This was a cross-sectional study of the prevalence of NTM among adults aged 15 years and above, who were participants in a national TB prevalence survey. All individuals with an abnormal chest x-ray or positive symptom screening result (i.e. cough or chest pain, or fever lasting more than 2 weeks or more) were requested to submit two sputum samples; one on the spot and another in the morning. The samples were then transported in cooler boxes packed with cold gel within 24 h of collection to each of the three central reference laboratories (CRLs) for processing. At the laboratories, the sputum samples were first decontaminated in 1 % sodium hydroxide (NaOH) working solution for 15 min and then stained for AFB using the Auramine-Phenol method. The smears were graded as smear positive for mycobacterial infection using both qualitative and quantitative grading methods. Thereafter, the samples were cultured using liquid media by mycobacteria growth indicator tube (MGIT) (BD BACTEC$^\text{TM}$). Mycobacterial growth was detected and identified as either MTB or NTM using the capilia (TAUNS) method. The laboratory team was blinded to the radiology or symptom status of the study participants; they only had a Personal Identification Number (PIN) and sample.

Before collection of sputum samples; each symptomatic survey participant also underwent an in-depth questionnaire. Initial reading of chest radiographs was done by medical officers in the field and classified as either normal or abnormal. All images subsequently underwent reading by expert radiologists who classified the images using a pre-defined criteria [21] as follows:

- N = Normal
- AD - NS = Abnormality detected - not significant
- ADS-NA = Abnormality detected, significant no active disease
- ADS-NTB = Abnormality detected, significant not-TB
- ADS-TB = Abnormality detected, significant TB

All the abnormal ‘not TB’ images were then re-read to further specify the abnormality so as to make a radiological diagnosis. The central reading by radiologists was performed independent of the microbiology results.
The HIV status for each of the NTM cases was established using the HIV testing results which were obtained using a separate consent during field level HIV screening of survey participants. The screening test used was Determine® HIV-1/2 (Inverness Medical Japan, Co, Ltd) and all positives were further confirmed by Unigold® HIV-1/2 (Trinity Biotech, Wicklow, Ireland). Discordant results (positive on Determine® but negative on Unigold®) were recorded as indeterminate.

At the central data management unit, the results of the symptom screening, chest x-ray screening and laboratory results were merged to create one final database for analysis. The files were merged using PINs which were unique to each participant in the survey. This was done to ensure that for each NTM, data on radiology, clinical history and microbiology was complete. Only the data manager had access to the complete merged data set. This was done to ensure confidentiality but also to reduce bias during case detection or diagnosis.

Data analysis was performed using STATA version 12. Means and frequencies were generated taking into account of the Random Standard Errors using the default “svy” command during analysis.

Chi-square tests were performed to establish relationship between the categorical or binary variables. Linear regression analysis was done to show the association between NTM and different exposure variables such as HIV status, smear positivity, history of cough or chest pain or fever.

The prevalence of NTM was estimated using cluster level and individual level analysis as recommended by Floyd et al. [22].

The study protocol was cleared by the University of Zambia Biomedical Research Ethics Committee (UNZABREC) No: 020-08-12. Authorisation to conduct the survey was sought in line with the existing national policies and guidelines at national, provincial and district levels. Written informed consent was obtained from all individuals who agreed to participate in the survey.

Results
Of the 6,123 with presumptive MTB, 923 (15.1 %) were found to have NTM, 265 (4.3 %) were MTB, 13 (0.2 %) were MTB/NTM co-infected and 338 (5.5 %) were contaminated (indeterminant). Basic cohort characteristics are shown in Table 1. Most of the participants with NTM were from the lowest-wealth quintile. 71 % of the NTM infected participants were symptomatic, either having a cough and/or chest pain and/or fever for two weeks or more. 52 % of NTM infected participants had an abnormal field chest x-ray reading. 23 % (210) of the participants with NTM were both symptomatic and had an abnormal CXR reading at field level. Chest x-ray results were not available for 2/923 participants with NTM.

Some of the abnormal chest radiographs showed evidence of bronchiectasis, nodules, fibrosis or cavitation as shown in Table 2. Majority of the participants with NTM had negative smear (94.5 %) and 62 % were HIV negative.

Comparing the three cardinal symptoms collected in the survey (Table 3); 277 individuals with NTM had no history of either cough or chest pain or fever and 52 reported a history of fever only without any of the other two (chest pain and cough). A total of 423 individuals reported having all the three symptoms.
The risk factors of NTM included smear positivity; history of cough or chest pain or fever or weight loss and being HIV positive as shown in Table 4.

Prevalence of symptomatic NTM among TB survey participants aged 15 years and above was found to be 1,477/100,000 [95 % CI 1010–1943]. Symptomatic NTM prevalence was found to be significantly higher among the rural than urban participants (1927 vs 642/100,000 population). However, there was no significant difference in the prevalence of symptomatic NTM by sex (1,577/100,000 versus 1403/100,000). Among the provinces, NTM prevalence was highest in Western (9,824/100,000) and lowest in Copperbelt (309/100,000) (Table 5). The participation rate for Western province was low hence this may have resulted into the wide confidence interval of the prevalence estimate.

The prevalence of symptomatic NTM increased with participant’s age from 452/100,000 among those aged 15–24 years to 5160/100,000 among those aged 65 years and above. The symptomatic NTM prevalence was highest among the lower wealth quintiles and participants without schooling. Participants with bacteriologically confirmed MTB had significantly higher symptomatic NTM prevalence than those without (6773 vs 1468/100,000). Participants with smear positive TB had a higher prevalence of symptomatic NTM than those with a negative smear (8527 vs 1479/100,000). Considering HIV status, the HIV positive participants had higher symptomatic NTM prevalence than the HIV negative counterparts (2187 vs 1549/100,000) but the difference was not significant.

Discussion
This study represents a first attempt to quantify NTM prevalence nation-wide in Zambia. The focus was on individuals with NTM coupled with both symptom and radiological profiles. The high prevalence of NTM among symptomatic participants found in this population based study demonstrates that NTM is a public health problem. There is a need to further identify the species and come up with case management guidelines in order to appropriately manage the people in whom NTM is causing illness. Symptomatic NTM prevalence was found to be approximately two times higher than MTB and 14 % of the smear positives were found to be NTM [23]. Therefore, NTM patients could potentially be mismanaged as MTB. Besides a public health issue this is also an ethical issue requiring no further neglect. Although the World Health Organization (WHO) has described Neglected Tropical Diseases (NTDs), this list conspicuously does not yet include any of the NTM.

As smears are routinely used to diagnose TB and to initiate treatment, it could be that symptomatic NTM cases seeking care in health facilities are misdiagnosed and placed on TB treatment. Without adequate clinical response, these cases may subsequently be misdiagnosed as TB treatment failures. Thus, false MTB-positives may in fact be clinical NTM and if the treatment outcomes do not improve; the patient may mistakenly be classified as MDR-TB. Such patient mismanagement may negatively impact the health status of the individual and consequently pose additional cost to the health system. Therefore, appropriate NTM case management is required in order to effectively and efficiently manage the MTB problem.
Table 5 Symptomatic Non-tuberculous mycobacteria prevalence per 100,000 adult population

| Variable                        | Prevalence estimate | 95 % Confidence interval |
|---------------------------------|---------------------|--------------------------|
| Overall                         | 1477                | 1010–1943                |
| Setting                         |                     |                          |
| Rural                           | 1927                | 1244–2611                |
| Urban                           | 642                 | 332–951                  |
| Sex                             |                     |                          |
| Male                            | 1577                | 1140–2014                |
| Female                          | 1403                | 885–1922                 |
| Age group (years)               |                     |                          |
| 15–24                           | 452                 | 268–639                  |
| 25–34                           | 1010                | 649–1371                 |
| 35–44                           | 1394                | 943–1844                 |
| 45–54                           | 2038                | 1247–2829                |
| 55–64                           | 2803                | 1575–4032                |
| 65+                             | 5160                | 3619–6702                |
| Age group (years) and sex       |                     |                          |
| Male 15–34                      | 712 (447–976)       | 661 (392–930)            |
| Female 15–34                    | 661 (392–930)       | 612 (354–980)            |
| 35–54                           | 1911 (1363–2460)    | 1778 (954–2601)          |
| Female 35–54                    | 1778 (954–2601)     | 1620 (904–2536)          |
| 55+                             | 4124 (2822–5426)    | 3841 (1975–5707)         |
| Wealth quintile                 |                     |                          |
| Lowest                          | 2582                | 1628–3535                |
| Second lowest                   | 2638                | 1635–3640                |
| Middle                          | 1773                | 1121–2424                |
| Fourth                          | 778                 | 359–1196                 |
| Highest                         | 464                 | 285–643                  |
| Education level                 |                     |                          |
| No schooling                    | 3495                | 2010–4980                |
| Primary school                  | 1858                | 1301–2415                |
| Secondary school                | 752                 | 512–992                  |
| Tertiary education              | 339                 | 19–658                   |
| Bacteriological Tuberculosis status |                 |                          |
| Negative                        | 1468                | 996–1940                 |
| Positive                        | 6773                | 3453–10093               |
| Smear Tuberculosis status       |                     |                          |
| Negative                        | 1479                | 1007–1951                |
| Positive                        | 8527                | 3180–13874               |
| HIV status                      |                     |                          |
| HIV negative                    | 1549                | 1008–2090                |
| HIV positive                    | 2187                | 1428–2946                |
| HIV status unknown              | 1249                | 863–1635                 |
| By Province                     |                     |                          |
| Central                         | 3222                | 739–5706                 |
| Copperbelt                      | 309                 | 161–458                  |
| Eastern                         | 695                 | 411–979                  |
| Luapula                         | 2150                | 524–3777                 |
The radiological abnormalities for NTM observed in this survey are consistent with what has been reported elsewhere [5]. The pulmonary presentation of NTM was characterized by the presence of bronchiectasis; cavitation; pneumoconiosis, fibrosis and nodules. The cardinal symptoms of fever, chest pain and unintentional weight loss were prevalent in the survey participants with NTM. This may suggest that NTM in Zambia is causing symptomatic disease.

The higher NTM prevalence among HIV positive individuals brings a further challenge of managing NTM/HIV and its associated side effects for potential patients. Even though, the burden of NTM was higher among the HIV positive, there is also a substantial burden among the HIV negative that cannot be ignored.

The NTM prevalence in Zambia seems to increase with age. This was true for both male and female supporting earlier evidence from Greece and the United States of America [5, 24, 25]. Nonetheless, it will be important to establish if the species causing disease are occurring in similar proportions among the male and females since reported symptoms were found to differ by gender.

Studies from Nigeria, Tanzania and South Africa have shown that NTMs may be occurring among patients seeking care for MTB [15, 16, 26] with varying frequency by geographical locations [27]. The NTM prevalence isolated in this Zambia survey is higher than what was found in Oregon in the United States of America and Ontario in Canada [28, 29]. However, the differences in the study population and analytical approach partially contribute to the variations. Our study also suggests potential interaction or misdiagnosis with MTB as in the American and Canada studies. Therefore, a comprehensive multi-country evaluation of NTM is needed to better understand the extent of the NTM burden on the globe and design strategic action.

Table 5 Symptomatic Non-tuberculous mycobacteria prevalence per 100,000 adult population (Continued)

| Region       | Male (100,000) | Female (100,000) |
|--------------|----------------|------------------|
| Lusaka       | 729            | 395–1062         |
| Muchinga     | 3794           | 1818–5771        |
| Northern     | 1217           | 650–1784         |
| North Western| 1688           | 1077–2299        |
| Southern     | 822            | 294–1349         |
| Western      | 9824           | 3767–15881       |

A potential limitation is that the study was conducted within the national TB prevalence survey design, as a result, we are unable to fully apply the existing NTM disease classification criteria because the methods used for sputum collection were with the primary purpose of estimating MTB prevalence. However, the availability of samples from various subnational levels provides opportunity for better estimation of the NTM burden and provides geographic guidance for potential programmatic focus.

This study is the first attempt to estimate the national burden of NTM in Zambia. Further studies are recommended to fully understand causal and etiological pathways.

Conclusions

Our data confirm that the problem of NTM is substantial in Zambia. Synopsis of epidemiological, clinical and radiological information is needed to support an informed decision on whether a patient has disease resulting from MTBC or NTM infection. Rigorous surveillance strategies are required to curb the further spread of this neglected mycobacterial disease.

Competing interests

None of the authors has any conflict of interest to declare.

Authors’ contributions

PK and NK conceived the idea, participated in the design, data collection, analysis and manuscript development. EK participated in data analysis, interpretation of the data and reviewed the manuscript. LM, MT, PK, VS participated in design, data collection, conducted laboratory or radiology procedures and reviewed the manuscript. PM and MPG participated in interpretation of the data, reviewed the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The data collection was supported by the Government of The Republic of Zambia (GRZ) through The United States Agency for International Development (USAID) in Zambia; and Centres for Disease Control and Prevention (CDC) Zambia. The authors wish to acknowledge the dedication of research assistants at the field, laboratory, radiology and central data management unit.

Author details

1Department of Disease Surveillance, Control and Research, Ministry of Health, Lusaka, Zambia.
2Center of Tropical Medicine and Travel Medicine, Amsterdam Medical Centre, University of Amsterdam, Amsterdam, Netherlands.
3Department of Epidemiology and Disease Control, Ministry of Health, Lusaka, Zambia.
4KNCV Tuberculosis Foundation, The Hague, Netherlands.
Global Health and Development, Amsterdam Medical Centre, Amsterdam, Netherlands. 4 Department of Clinical Care and Diagnostics, Chest Diseases Laboratory, Ministry of Health, Lusaka 10101, Zambia. 5 Tuberculosis Laboratory, Tropical Diseases Research Centre, Ndola, Zambia. 6 Tuberculosis Laboratory, University Teaching Hospital, Lusaka 10101, Zambia. 7 Radiology Department, University Teaching Hospital, Lusaka 10101, Zambia.

Received: 1 April 2015 Accepted: 5 November 2015 Published online: 06 November 2015

References

1. Jamison DT. Disease and Mortality in Sub-Saharan Africa. Washington World Bank Publications; 2006. p. 180.

2. Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest. 2004;126(2):566–81.

3. van Ingen J. Diagnosis of nontuberculous mycobacterial infections. Semin Respir Crit Care Med. 2013;34(1):109.

4. Falkhenr III JG. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev. 1996;9(2):177–215.

5. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416. doi:10.1164/rccm.200604-517ST.

6. Johnson WM, Odell JA. Non-tuberculosis mycobacterial pulmonary infections. J Thorac Dis. 2014;6(S3):210–20. doi:10.7196/JTD.2013.224.

7. Aksamit TR, Philley JV, Griffith DE. Nontuberculous mycobacterial (NTM) lung disease: The top ten essentials. Respir Med. 2013;107:417–25.

8. Satyanarayana G, Heysell KS, Scully KW, Houpt ER. Mycobacterial infections in a large Virginia hospital, 2001–2009. BMC Infect Dis. 2011;11:113. doi:10.1186/1471-2334-11-113.

9. Matveychuk A, Fuku L, Priest R, Ahirn I, Shtrit D. Clinical and radiological features of Mycobacterium kansasi and other NTM infections. Respir Med. 2012;106:1472–7.

10. dos Santos RP, Scheid KL, Willers DM, Goldani LZ. Comparative radiological features of disseminated disease due to Mycobacterium tuberculosis vs non-tuberculosis mycobacteria among AIDS patients in Brazil. BMC Infect Dis. 2008;8:24. doi:10.1186/1471-2334-8-24.

11. Taiwo B, Glasroth J. Nontuberculous mycobacterial lung diseases. Infect Dis Clin North Am. 2012;24(3):769–89.

12. Pokam BT and Asuquo AE: Acid-Fast Bacilli Other than Mycobacteria in Tuberculosis Patients Receiving Directly Observed Therapy Short Course in Cross River State, Nigeria. Tuberculosis Research and Treatment 2012; Article ID 301056, 4 pages, 2012. doi:10.1155/2012/301056.

13. Cook VI, Turetteme CF, Wolfe J, Paats R, Kabani A. Conventional methods versus 16S ribosomal DNA sequencing for identification of non-tuberculous mycobacteria: Cost analysis. J Clin Microbiol. 2003;41(3):1010–5.

14. Zykov MP, Roulet H, Gaya N. Non-tuberculosis mycobacteria in Africa: Isolation and identification. Bull World Health Organ. 1967;37(6):927–38.

15. Aliyu G, El-Kamary S, Abimiku A, Brown C, Tracy K, Hungerford L, et al. Invasive disease caused by nontuberculous mycobacteria. J Clin Microbiol Rev. 1996;9(2):177–215.

16. Crump AJ, Ramadhan HO, Morrissey BA, Saganda W, Mwako MS, Yang L, et al. Nontuberculous mycobacteria. Tanzania Emerg Infect Dis. 2009;15(1):153–5.

17. Henkle E, Winthrop KL. Nontuberculous mycobacteria in immunosuppressed hosts. Clin Chest Med. 2015;36(1):91–9. doi:10.1016/j.ccm.2014.11.002.

18. Bonard D, Messou E, Seyler C, Vincent V, Gabilard D, Anglaret X. High incidence of atypical mycobacteriosis in African HIV-infected adults with low CD4 cell counts: a 6-year cohort study in Cote d’Ivoire. AIDS. 2004;18:1961–4.

19. Buijtels PC, van der Sande MA, Parkinson S, Verbrugh HA, Pett P, van Soolingen D. Isolation of non-tuberculosis mycobacteria at three rural settings in Zambia; a pilot study. Clin Microbiol Infect. 2010;16:1142–8.

20. Buijtels PC, van der Sande MA, de Graaff CS, Parkinson S, Verbrugh HA, Pett PLC, et al. Non-tuberculous mycobacteria. Zambia Emerg Infect Dis. 2009;15(2):242–9.

21. World Health Organization. Tuberculosis Prevalence Surveys: a handbook. WHO/HTM/TB/2011.17. WHO, Geneva, Switzerland. Available [Online] from: http://www.who.int/tb/advisory_bodies/impact_measurement_taskforce/resources_documents/limebook_appendix/en/